- About ARF
- Make a Difference
- Research Studies
- Contact Us
JA Jarvinen PhD, DVM, Department of Veterinary Pathology, College of Veterinary Medicine, Iowa State University, Ames, IA 50011-1250 USA
The following presentation was made at the IV World Camelid Congress in Santa Maria, Catamarca Argentina on October 13, 2006.
BVDV has emerged as a significant pathogen in alpacas in North America where persistently infected crias have been documented. To assess the extent of BVDV infection/exposure in the US national herd, a serologic survey was initiated in April 2006. A request to participate in the study was mailed to 550 randomly selected herd owners representing approximately 10% of herds per state. Participants were asked to submit blood samples from up to five alpacas in their herd between April 1 and July 31, 2006, for testing in a virus neutralization assay. Preliminary results available as of 7-15-06 indicate samples were received from 27 herds in 17 states; five herds (18.5%) in three states (MI, NM and NY) had seropositive alpacas. Of 132 samples from individual alpacas, 12 (9.1%) had titers against BVDV Type I and/or Type 2. In positive herds, from 20 to 80% of alpacas tested were seropositive; BVDV Type 1 titers ranged from 2 to 1024 while Type 2 titers ranged from <2 to 128. Although all positive alpacas were huacayas, only 16.7% of all alpacas sampled were sun. Seropositive animals ranged from 8 months to 9 years of age. Cattle were present on 1/5 farms (20%) with seropositive herds and 2/22 farms (9.1%) with seronegative herds.